1.08
전일 마감가:
$1.12
열려 있는:
$1.14
하루 거래량:
1.28M
Relative Volume:
0.74
시가총액:
$103.48M
수익:
-
순이익/손실:
$-93.61M
주가수익비율:
-0.5118
EPS:
-2.11
순현금흐름:
$-71.16M
1주 성능:
+15.93%
1개월 성능:
+54.29%
6개월 성능:
+10.15%
1년 성능:
-25.52%
Immunic Inc Stock (IMUX) Company Profile
명칭
Immunic Inc
전화
(332) 255-9818
주소
1200 AVENUE OF THE AMERICAS, NEW YORK
IMUX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
IMUX
Immunic Inc
|
1.08 | 107.32M | 0 | -93.61M | -71.16M | -2.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-25 | 개시 | William Blair | Outperform |
2024-11-25 | 개시 | H.C. Wainwright | Buy |
2024-09-09 | 재개 | Leerink Partners | Outperform |
2024-08-27 | 개시 | B. Riley Securities | Buy |
2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2022-09-19 | 재개 | H.C. Wainwright | Buy |
2021-04-15 | 개시 | Aegis Capital | Buy |
2021-03-24 | 개시 | JMP Securities | Mkt Outperform |
2020-10-02 | 개시 | SVB Leerink | Outperform |
2020-08-26 | 개시 | Piper Sandler | Overweight |
2020-08-07 | 재개 | ROTH Capital | Buy |
2020-07-20 | 개시 | BMO Capital Markets | Outperform |
2020-06-05 | 개시 | Wedbush | Outperform |
2020-05-11 | 개시 | H.C. Wainwright | Buy |
2020-03-25 | 개시 | ROTH Capital | Buy |
2019-07-11 | 개시 | Chardan Capital Markets | Buy |
모두보기
Immunic Inc 주식(IMUX)의 최신 뉴스
What is the dividend policy of Immunic Inc. stockBuild wealth with long-term growth strategies - jammulinksnews.com
What are analysts’ price targets for Immunic Inc. in the next 12 monthsCapitalize on emerging market trends - jammulinksnews.com
Should I hold or sell Immunic Inc. stock in 2025Triple-digit profit margins - jammulinksnews.com
Is it the right time to buy Immunic Inc. stockFree Predictions - jammulinksnews.com
When is Immunic Inc. stock expected to show significant growthIdentify safe investments with exceptional yields - jammulinksnews.com
Is Immunic Inc. a growth stock or a value stockAchieve rapid portfolio growth with smart picks - jammulinksnews.com
What are the technical indicators suggesting about Immunic Inc.Free Consultation - jammulinksnews.com
What is Immunic Inc. company’s growth strategyBreakthrough profit margins - jammulinksnews.com
Immunic, Inc.'s (NASDAQ:IMUX) market cap touched US$103m last week, benefiting both individual investors who own 55% as well as institutions - simplywall.st
Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial - Yahoo Finance
What drives Immunic Inc. stock priceRapid return acceleration - Autocar Professional
What analysts say about Immunic Inc. stockRecord-breaking gains - PrintWeekIndia
How Immunic Inc. stock reacts to Fed policy changesPowerful profit generation - jammulinksnews.com
Immunic Inc. Stock Analysis and ForecastRapid growth opportunities - Autocar Professional
How high can Immunic Inc. stock price go in 2025Accelerated earnings growth - jammulinksnews.com
Is Immunic Inc. a good long term investmentBreakthrough profits - PrintWeekIndia
Immunic, Inc. shares fall 2.01% premarket after AstraZeneca's immune disorder drug succeeds in late-stage trial. - AInvest
12 Best Penny Stocks Under $1 to Buy Now - Insider Monkey
World Brain Day: Immunic targets MS with new therapy - Proactive financial news
IMUX’s Stock Market Puzzle: Piecing Together 2025’s Performance - investchronicle.com
What makes Immunic Inc. stock price move sharplyValue Pick Scanner - Newser
How Immunic Inc. stock performs during market volatilityFree Top Growth Stock Recommendations - Newser
Why Immunic Inc. stock attracts strong analyst attentionFree Capital Allocation Plans - Newser
Immunic Inc (IMUX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):